Lawrence Blonde

ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 24

Top Venues

Diabetes, obesity & metabolism

Diabetes care

Advances in therapy

Postgraduate medicine

Ochsner Medical Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Ochsner Medical Center Aug 01 1974

United States

Director, Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute :: Department of Endocrinology

Publications

Vanita R Aroda, Lawrence Blonde, Richard E Pratley
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in endocrine & metabolic disorders 23 (5) (2022)
Matthew C Riddle, null null, George L Bakris, Lawrence Blonde, Andrew J M Boulton, Jessica R Castle, Linda A DiMeglio, Linda Gonder-Frederick, Frank B Hu, Steven E Kahn, Sanjay Kaul, Robert Geoffrey Moses, Stephen S Rich, Julio Rosenstock, Elizabeth Selvin, Adrian Vella, Judith Wylie-Rosett
Editorial Cycles and Continuity of Diabetes Care. Diabetes care 45 (7) (2022)
Richard Milani, Pavan Chava, Jonathan Wilt, Jonathan Entwisle, Susan Karam, Jeffrey Burton, Lawrence Blonde
Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort Study. JMIR diabetes 6 (2) (2021)
Julio Rosenstock, Lawrence Blonde, Vanita R Aroda, Juan Pablo Frias, Elisabeth Souhami, Chen Ji, Elisabeth Niemoeller, Stephano Del Prato
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. Diabetes, obesity & metabolism 23 (6) (2021)
Lawrence Blonde, Udi Fainberg, Margit S Kaltoft, Lawrence A Leiter, Chethana Ramesh, Rosangela Rea
Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i. Diabetes, obesity & metabolism 23 (10) (2021)
Lawrence Blonde, Timothy S Bailey, Sean D Sullivan, Nick Freemantle
Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme. Diabetes, obesity & metabolism 23 (8) (2021)
Lawrence Blonde, Julio Rosenstock, Juan Pablo Frias, Andreas L Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stephano Del Prato, Vanita R Aroda
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes care 44 (3) (2021)
Philip D Home, Lawrence Blonde, Sanjay Kalra, Li-Nong Ji, Patricia Guyot, Claire Brulle-Wohlhueter, Erin Murray, Roshan Shah, Toby Sayre, Alka Shaunik
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. Diabetes, obesity & metabolism 22 (11) (2020)
Xuejun Victor Peng, Rory J McCrimmon, Leah Shepherd, Anders Boss, Robert Lubwama, Terry Dex, Neil Skolnik, Linong Ji, Angelo Avogaro, Lawrence Blonde
Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. Diabetes therapy : research, treatment and education of diabetes and related disorders 11 (11) (2020)
Stephano Del Prato, Juan Pablo Frias, Lawrence Blonde, Vanita R Aroda, Niam Shehadeh, Aramesh Saremi, Terry Dex, Elisabeth Niemoeller, Elisabeth Souhami, Minzhi Liu, Julio Rosenstock
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial. Diabetes, obesity & metabolism 22 (9) (2020)
Lawrence Blonde, Lidia Belousova, Udi Fainberg, Pedro A Garcia-Hernandez, Sunil M Jain, Margit S Kaltoft, Ofri Mosenzon, Jalal Nafach, Mads Sundby Palle, Rosangela Rea
Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism 22 (6) (2020)
Frank Lavernia, Lawrence Blonde
Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgraduate medicine 132 (sup2) (2020)
Stephen H Mandy, Lawrence Blonde, Jasvinder Gill, Arnaud Dauchy, Andrius Bacevicius, Jodi Strong, Timothy S Bailey
Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial. Diabetes, obesity & metabolism 22 (11) (2020)
Philip D Home, Vanita R Aroda, Lawrence Blonde, Patricia Guyot, Alka Shaunik, Mir Sohail Fazeli, Hardik Goswami, Sanjay Kalra, Mir-Masoud Pourrahmat
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison. Diabetes, obesity & metabolism 22 (11) (2020)
Lawrence Blonde, Timothy S Bailey, Jason Chao, Terry A Dex, Juan Pablo Frias, Luigi F Meneghini, Michelle Roberts, Vanita R Aroda
Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Advances in therapy 36 (9) (2019)
Timothy S Bailey, Jasmanda Wu, Fang Liz Zhou, Rishab A Gupta, Arjun A Menon, Paulos Berhanu, Jukka Westerbacka, John Van Vleet, Lawrence Blonde
Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3). Diabetes, obesity & metabolism 21 (11) (2019)
Timothy S Bailey, Fang Liz Zhou, Rishab A Gupta, Ronald Preblick, Vineet E Gupta, Paulos Berhanu, Lawrence Blonde
Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study. Diabetes, obesity & metabolism 21 (7) (2019)
Lawrence Blonde, Julio Rosenstock, Stephano Del Prato, Robert R Henry, Naim Shehadeh, Juan Pablo Frias, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Vanita R Aroda
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes care 42 (11) (2019)
Lawrence Blonde, Kamlesh Khunti, Stewart B Harris, Casey Meizinger, Neil S Skolnik
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in therapy 35 (11) (2018)
Philip D Home, Francoise Calvi-Gries, Lawrence Blonde, Valerie Pilorget, Joseph Berlingieri, Nick Freemantle
Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. Diabetes, obesity & metabolism 20 (4) (2018)
Olga Montvida, Jonathan Edward Shaw, Lawrence Blonde, Sanjoy K Paul
Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study. Diabetes, obesity & metabolism 20 (7) (2018)
Sean D Sullivan, Timothy S Bailey, Ronan Roussel, Fang Liz Zhou, Zsolt Bosnyak, Ronald Preblick, Jukka Westerbacka, Rishab A Gupta, Lawrence Blonde
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes, obesity & metabolism 20 (9) (2018)
Lawrence Blonde, Susana Dipp, Daniel Cadena
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. Advances in therapy 35 (7) (2018)
Fang Liz Zhou, Fen Ye, Paulos Berhanu, Vineet E Gupta, Rishab A Gupta, Jennifer Sung, Jukka Westerbacka, Timothy S Bailey, Lawrence Blonde
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes, obesity & metabolism 20 (5) (2018)

Lawrence Blonde.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lawrence Blonde